Eosinophilic fasciitis induced by nivolumab therapy managed without treatment interruption or systemic immunosuppression.

Bui, Ai-Tram N; Nelson, Caroline A; Lian, Christine G; Canales, Alvaro Laga; LeBoeuf, Nicole R

Bui, Ai-Tram N; Nelson, Caroline A; Lian, Christine G; Canales, Alvaro Laga; LeBoeuf, Nicole R.

Afiliación

Bui AN; Harvard Medical School, Boston, Massachusetts.
Nelson CA; Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
Lian CG; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Canales AL; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
LeBoeuf NR; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.

JAAD Case Rep ; 6(8): 693-696, 2020 Aug.

Article en En | MEDLINE | ID: mdl-32715051

Palabras clave

EF, eosinophilic fasciitis; ICI, immune checkpoint inhibitor; MRI, magnetic resonance imaging; PD-1/L1 inhibition; PFTs, pulmonary function tests; ROM, range of motion; autoimmunity; checkpoint inhibition; cutaneous toxicities; eosinophilic fasciitis; immune checkpoint inhibitors; immune-related adverse event; irAE, immune-related adverse event

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JAAD Case Rep Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google